Patent Oppositions in cancer drugs industry

Explore the competitive field of cancer drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in cancer drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the cancer drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the cancer drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 6, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 29, 2026STORZ
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 28, 2026PAJARO
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 27, 2026GREINER
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEJul 22, 2026ABBOTT PRODUCTION OPERATIONS
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 17, 2026POHLMAN
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 13, 2026MANZER
Drug Delivery Systems And Methods For Treatment Of Bladder Cancer With GemcitabineTARIS BIOMEDICALJun 10, 2026GRUND GROUP PATENTANWALTE UND SOLICITOR PARTG MBB
Sotorasib Dosing RegimenAMGENMay 26, 2026BOTTI & FERRARI
Low Calorie Food Preparation For The Nutrition Of Cancer PatientsFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORIMay 19, 2026L NUTRA
Neutralization Of Inhibitory Pathways In LymphocytesINNATE PHARMAMay 13, 2026STRAWMAN

To stay ahead in the competitive cancer drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the cancer drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 6, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY24
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE17
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE15
Jan 7, 2026Formulations Of EnzalutamideASTELLAS PHARMA14
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB11
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI11
Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS10
May 20, 2015Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTIS9